Loading...
XNASCYCC
Market cap2mUSD
Dec 24, Last price  
0.32USD
1D
-1.69%
1Q
-68.64%
Jan 2017
-99.98%
Name

Cyclacel Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:CYCC chart
P/E
—
P/S
4.79
EPS
—
Div Yield, %
9.99%
Shrs. gr., 5y
7.07%
Rev. gr., 5y
22.87%
Revenues
420k
62,000813,000387,000129,000877,000911,000686,000699,00069,0001,084,0001,734,0001,944,000843,0000150,0000000420,000
Net income
-23m
L+6.40%
-39,588,000-29,416,000-29,258,000-24,053,000-40,386,000-19,570,000-16,021,000-15,243,000-13,186,000-10,153,000-19,387,000-14,342,000-11,791,000-7,470,000-7,288,000-7,828,000-8,445,000-18,887,000-21,198,000-22,555,000
CFO
-16m
L-22.64%
-21,086,000-21,510,000-20,172,000-23,140,000-29,905,000-15,193,000-16,044,000-13,977,000-12,043,000-18,199,000-18,702,000-14,460,000-10,079,000-7,480,000-6,701,000-9,447,000-7,934,000-18,540,000-20,827,000-16,111,999
Dividend
Jul 13, 20160.0075 USD/sh
Earnings
Mar 17, 2025

Profile

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
URL
https://cyclacel.com/
IPO date
Jan 01, 1996
Employees
12
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
420
 
Cost of revenue
25,873
27,688
22,981
Unusual Expense (Income)
NOPBT
(25,453)
(27,688)
(22,981)
NOPBT Margin
Operating Taxes
(2,996)
(4,717)
(3,847)
Tax Rate
NOPAT
(22,457)
(22,971)
(19,134)
Net income
(22,555)
6.40%
(21,198)
12.24%
(18,887)
123.65%
Dividends
(201)
(201)
(201)
Dividend yield
8.85%
3.05%
0.58%
Proceeds from repurchase of equity
1,049
3,199
21,938
BB yield
-46.18%
-48.62%
-63.18%
Debt
Debt current
Long-term debt
74
212
60
Deferred revenue
Other long-term liabilities
4,494
Net debt
(3,304)
(18,133)
(36,499)
Cash flow
Cash from operating activities
(16,112)
(20,827)
(18,540)
CAPEX
(6)
(7)
(27)
Cash from investing activities
(6)
(7)
(27)
Cash from financing activities
848
2,998
21,737
FCF
(21,668)
(23,051)
(17,895)
Balance
Cash
3,378
18,345
36,559
Long term investments
Excess cash
3,357
18,345
36,559
Stockholders' equity
(429,189)
(398,476)
(385,697)
Invested Capital
429,833
418,585
422,990
ROIC
ROCE
EV
Common stock shares outstanding
851
658
595
Price
2.67
-73.31%
10.01
-82.85%
58.35
-50.19%
Market cap
2,272
-65.47%
6,579
-81.05%
34,723
22.36%
EV
(1,032)
(7,060)
(1,776)
EBITDA
(25,422)
(27,656)
(22,938)
EV/EBITDA
0.04
0.26
0.08
Interest
2,006
Interest/NOPBT